TDMS Study 89006-06 Pathology Tables
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
TWO-YEAR CHRONIC
Facility: Southern Research Institute
Chemical CAS #: 30516-87-1
Lock Date: 06/04/93
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 5 5 9 7
Natural Death 11 6 7 11
Dosing Accident 2 1
Accidently Killed 1
Survivors
Terminal Sacrifice 34 38 31 31
Natural Death 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (48) (44) (49) (45)
Intestine Large, Rectum (46) (48) (46) (45)
Squamous Cell Carcinoma, Metastatic, Vagina 1 (2%)
Intestine Small, Jejunum (46) (46) (44) (42)
Intestine Small, Ileum (46) (44) (45) (42)
Liver (50) (50) (50) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (4%)
Hepatoblastoma 1 (2%) 2 (4%)
Hepatocellular Carcinoma 10 (20%) 14 (28%) 10 (20%) 11 (22%)
Hepatocellular Carcinoma, Multiple 2 (4%) 3 (6%) 1 (2%) 4 (8%)
Hepatocellular Adenoma 14 (28%) 11 (22%) 9 (18%) 19 (38%)
Hepatocellular Adenoma, Multiple 6 (12%) 7 (14%) 8 (16%) 9 (18%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Mesentery (13) (17) (8) (11)
Carcinoma, Metastatic, Pancreas 1 (8%)
Carcinoma, Metastatic, Uterus 1 (6%)
Fibrosarcoma, Metastatic, Skeletal Muscle 1 (8%)
Histiocytic Sarcoma 1 (6%) 1 (13%)
Sarcoma 2 (15%)
Sarcoma, Metastatic, Pancreas 1 (9%)
Pancreas (50) (49) (49) (48)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (49) (49) (49) (49)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Page 2
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Papilloma 3 (6%) 3 (6%) 1 (2%) 1 (2%)
Stomach, Glandular (49) (49) (48) (49)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Pancreas 1 (2%)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (50) (50) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (50) (50)
Histiocytic Sarcoma 1 (2%)
Capsule, Carcinoma, Metastatic, Uterus 1 (2%)
Capsule, Fibrosarcoma, Metastatic, Skeletal
Muscle 1 (2%)
Islets, Pancreatic (49) (49) (50) (47)
Adenoma 2 (4%) 1 (2%) 1 (2%)
Pituitary Gland (46) (49) (46) (46)
Pars Distalis, Adenoma 2 (4%) 5 (10%) 1 (2%)
Thyroid Gland (49) (50) (50) (50)
Follicular Cell, Adenoma 3 (6%) 2 (4%) 4 (8%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (49) (49) (49) (48)
Carcinoma 1 (2%)
Ovary (50) (50) (47) (48)
Cystadenoma 2 (4%) 2 (4%) 3 (6%)
Granulosa Cell Tumor Benign 2 (4%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Teratoma Benign 1 (2%)
Page 3
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Uterus (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Leiomyosarcoma 1 (2%)
Endometrium, Carcinoma 1 (2%) 1 (2%)
Endometrium, Polyp Stromal 1 (2%) 2 (4%)
Endometrium, Sarcoma Stromal 1 (2%)
Vagina (50) (49) (45) (49)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma 5 (11%) 9 (18%)
Squamous Cell Papilloma 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (7) (5) (7) (10)
Fibrosarcoma, Metastatic, Skin 1 (10%)
Iliac, Histiocytic Sarcoma 1 (20%)
Inguinal, Carcinoma, Metastatic, Clitoral
Gland 1 (10%)
Inguinal, Histiocytic Sarcoma 1 (20%)
Mediastinal, Histiocytic Sarcoma 1 (14%)
Renal, Carcinoma, Metastatic, Clitoral Gland 1 (10%)
Renal, Histiocytic Sarcoma 1 (14%)
Lymph Node, Mandibular (50) (46) (48) (48)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node, Mesenteric (50) (47) (48) (47)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Spleen (49) (48) (49) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Pancreas 1 (2%)
Thymus (48) (46) (49) (46)
Carcinoma, Metastatic, Uterus 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (49) (50) (50)
Trichoepithelioma 1 (2%)
Pinna, Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 2 (4%) 2 (4%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Skeletal Muscle (50) (50) (50) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrosarcoma 1 (2%)
Hemangiosarcoma 1 (2%)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Pancreas 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 3 (6%) 2 (4%) 7 (14%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 5 (10%) 4 (8%)
Carcinoma, Metastatic, Clitoral Gland 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Fibrosarcoma, Metastatic, Skin 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 4 (8%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leiomyosarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic, Vagina 1 (2%)
Nose (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (5) (2) (2) (2)
Adenoma 4 (80%) 2 (100%) 1 (50%)
Carcinoma 1 (20%) 1 (50%) 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Urethra (1)
Squamous Cell Carcinoma, Metastatic, Vagina 1 (100%)
Urinary Bladder (50) (50) (49) (49)
Page 5
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 1 (2%) 3 (6%) 1 (2%)
Lymphoma Malignant 5 (10%) 10 (20%) 7 (14%) 9 (18%)
Mesothelioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 42 41 43
Total Primary Neoplasms 70 79 66 92
Total Animals with Benign Neoplasms 30 33 26 31
Total Benign Neoplasms 40 41 31 42
Total Animals with Malignant Neoplasms 26 30 28 35
Total Malignant Neoplasms 30 38 35 50
Total Animals with Metastatic Neoplasms 5 4 3 9
Total Metastatic Neoplasm 8 12 3 15
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 12 6 9 4
Moribund Sacrifice 6 9 9 4
Accidently Killed 2
Dosing Accident 1
Survivors
Terminal Sacrifice 32 35 29 42
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (49) (50)
Sarcoma, Metastatic, Skin 1 (2%)
Gallbladder (41) (42) (46) (44)
Intestine Large, Cecum (47) (48) (45) (49)
Intestine Small, Duodenum (48) (48) (47) (47)
Intestine Small, Jejunum (47) (48) (45) (47)
Carcinoma 1 (2%) 2 (4%) 1 (2%)
Intestine Small, Ileum (47) (48) (45) (47)
Liver (50) (50) (50) (50)
Hemangioma 2 (4%) 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%) 2 (4%) 3 (6%) 1 (2%)
Hemangiosarcoma, Multiple 5 (10%) 2 (4%) 1 (2%) 2 (4%)
Hepatoblastoma 1 (2%) 2 (4%) 5 (10%) 2 (4%)
Hepatoblastoma, Multiple 1 (2%)
Hepatocellular Carcinoma 17 (34%) 15 (30%) 15 (30%) 15 (30%)
Hepatocellular Carcinoma, Multiple 4 (8%) 11 (22%) 7 (14%) 4 (8%)
Hepatocellular Adenoma 17 (34%) 19 (38%) 14 (28%) 21 (42%)
Hepatocellular Adenoma, Multiple 8 (16%) 4 (8%) 9 (18%) 5 (10%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mesentery (1) (4) (5) (2)
Hepatocellular Carcinoma, Metastatic, Liver 1 (20%)
Sarcoma 1 (20%)
Pancreas (50) (49) (49) (50)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Salivary Glands (50) (49) (49) (50)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Page 8
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Forestomach (50) (48) (49) (50)
Stomach, Glandular (50) (48) (49) (50)
Sarcoma, Metastatic, Mesentery 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (49) (49)
Adenoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Capsule, Adenoma 5 (10%) 3 (6%) 1 (2%) 2 (4%)
Adrenal Medulla (50) (49) (48) (49)
Sarcoma, Metastatic, Mesentery 1 (2%)
Islets, Pancreatic (50) (49) (49) (50)
Adenoma 1 (2%) 1 (2%)
Thyroid Gland (50) (49) (48) (50)
Bilateral, Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 2 (4%) 3 (6%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
Tissue NOS (1) (1)
Hepatocellular Carcinoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (49) (50) (50)
Histiocytic Sarcoma 1 (2%)
Preputial Gland (48) (50) (50) (49)
Hemangiosarcoma 1 (2%)
Prostate (50) (49) (50) (50)
Seminal Vesicle (50) (49) (50) (50)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Testes (50) (49) (50) (50)
Page 9
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Lymph Node (6) (7) (5) (1)
Mediastinal, Sarcoma, Metastatic, Skin 1 (17%)
Popliteal, Hemangiosarcoma 1 (17%)
Renal, Histiocytic Sarcoma 1 (14%)
Lymph Node, Mandibular (49) (48) (49) (50)
Lymph Node, Mesenteric (48) (49) (49) (49)
Hemangiosarcoma 1 (2%)
Spleen (50) (49) (48) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%)
Thymus (41) (44) (41) (35)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Chondrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (50) (50) (50) (50)
Rhabdomyosarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
Cranial Nerve, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 8 (16%) 6 (12%) 9 (18%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 4 (8%) 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 2 (4%) 3 (6%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%)
Hepatoblastoma, Metastatic, Liver 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 2 (4%) 4 (8%) 3 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Nose (50) (50) (49) (50)
Schwannoma Malignant, Metastatic, Brain 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (7) (2) (10)
Adenoma 3 (100%) 2 (29%) 2 (100%) 10 (100%)
Carcinoma 3 (43%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (48) (49) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Renal Tubule, Adenoma 3 (6%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%)
Lymphoma Malignant 1 (2%) 6 (12%) 7 (14%) 5 (10%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT Date: 05/31/96
Route: GAVAGE Time: 12:48:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 49 45 50
Total Primary Neoplasms 90 96 91 88
Total Animals with Benign Neoplasms 33 31 29 42
Total Benign Neoplasms 49 42 42 51
Total Animals with Malignant Neoplasms 28 40 39 29
Total Malignant Neoplasms 41 54 49 37
Total Animals with Metastatic Neoplasms 6 3 9 3
Total Metastatic Neoplasm 13 3 22 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------